English Polski
Vol 22, No 1 (2016)
Research paper
Published online: 2016-09-29

open access

Page views 929
Article views/downloads 1352
Get Citation

Connect on Social Media

Connect on Social Media

Is rosuvastatin better than atorvastatin and simvastatin in the prevention of in-stent restenosis and atherosclerosis progression in patients after superficial femoral artery stenting due to chronic lower limb ischaemia? The preliminary case-control study

Jacek Budzynski, Joanna Kubiak, Grzegorz Pulkowski, Karol Suppan, Marcin Wasielewski, Joanna Wisniewska, Radoslaw Wieczor
Acta Angiologica 2016;22(1):5-11.

Abstract

Introduction. Statins effect on the outcome of endovascular intervention due to chronic lower limb ischaemia (CLLI) is still uncertain. The aim of this study was to determine the effect of statin type on the late outcome of superficial femoral artery (SFA) stenting in patients with CLLI.

Material and methods. Retrospective analysis of the medical documentation of 275 consecutive patients treated with SFA stenting due to CLLI, including 125 (45%) patients with critical limb ischaemia (CLI). Measured outcomes were: target lesion revascularization (TLR), target extremity revascularization (TER), and target limb amputation (TLA).

Results. Statins were used by 267 (97%) of the patients, respectively: atorvastatin (n = 191, 70%), simvastatin (n = 31, 11%) and rosuvastatin (n = 45, 16%). During the 675.0 ± 569.7 days of follow-up, TLR was required by 79 (29%) patients, TER by 109 (39%), and TLA by 27 (10%). Patients treated with rosuvastatin in comparison with those treated with atorvastatin, in spite of greater initial LDL and triglyceride levels, required TER (p = 0.01) and TLR (p = 0.03) less frequently. The risk of TER in patients treated with rosuvastatin was significantly (p = 0.016) lower than in individuals treated with atorvastatin and simvastatin, as shown in the Kaplan-Meier analysis. Cox’s proportional hazards regression showed that therapy with rosuvastatin was the strongest factor (HR 0.40 ± 95% CI; 0.2-0.81) decreasing the likelihood of TER.

Conclusions. Rosuvastatin after SFA stenting seems to have the strongest effect on reduction in reintervention risk but without influence on limb salvage.

Article available in PDF format

View PDF Download PDF file